prof. Sylvie Rottey
- Work address
-
C. Heymanslaan 10, ingang 12 - verdieping 2
9000 Gent - Sylvie.Rottey@UGent.be
- ORCID iD
-
0000-0003-2060-3725
Show
Sort by
-
A randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (Suniforecast)
-
'In-house' data on the outside : a mobile health approach
-
Targeting FGFR in bladder cancer : ready for clinical practice?
-
Safety, tolerability, and potential clinical activity of a glucocorticoid-induced TNF receptor-related protein agonist alone or in combination with nivolumab for patients with advanced solid tumors : a phase 1/2a dose-escalation and cohort-expansion clinical trial
-
On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors
-
- Conference Paper
- C3
- open access
Drug development from bench to bedside @UZGENT
-
Radiologic extranodal extension and outcome in cN + D TNM-8 stage I human papillomavirus-mediated oropharyngeal cancer : in regard to Billfalk-Kelly et al.
-
- Miscellaneous
- open access
Congress highlights – ASCO 2019 special edition: Highlights in genitourinary cancers
-
Algorithms for molecular testing in solid tumours
-
Mobile health technology captures 'in-house' data on the outside : an assessment with pharmacological intervention